Press Releases

January 25th, 2008
Neurotech Pharmaceuticals Announces Rhode Island Expansion Plan

November 6th, 2007
Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies

August 8th, 2007
Neurotech Names Richard Small Chief Financial Officer

April 17, 2007
Neurotech Initiates two Phase II/III Clinical Trials of NT-501 for the Treatment of Retinitis Pigmentosa

November 16, 2006
Neurotech TM, Inc. Completes $35 Million Private Equity Financing

March 15, 2006
Neurotech Announces Publication of NT-501 Phase I Results in Proceedings of the National Academy of Sciences

January 5, 2006
Neurotech Initiates a Phase II Clinical Trial of NT-501 for the Treatment of Dry Age Related Macular Degeneration

May 1, 2005
Neurotech Announces Successful Completion of Phase I

March 14, 2005
Neurotech Board Changes

November 24, 2003
Neurotech Completes Euro 12 Million Private Financing

October 8, 2003
Neurotech Announces Initiation of a Phase I Clinical Trial to Evaluate the Safety of Ciliary Neurotrophic Factor Implant in the Eye

March 24, 2003
Neurotech Strengthens Its Position In Ophthalmology Through Collaboration With Inserm and the Quinze-Vingts Hospital, Paris

December 3, 2002
Neurotech Reports in IOVS that Encapsulated Cell Based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa

August 23, 2002
Neurotech refocuses on ophthalmic technologies

April 26, 2002
Neurotech announces senior management changes

January 14, 2002
Neurotech signs license agreement with Amgen